Benazeprilat is the active metabolite of benazepril (sc-337551), formed after cleavage of the ester group. Benazeprilat is a potent inhibitor of angiotensin-converting enzyme (ACE). This prevents the conversion of angiotensin I to the vasoconstrictor angiotensin II.
1. Kitagawa, Hitoshi., et al., 2003. An angiotensin converting enzyme inhibitor, benazepril can be transformed to an active metabolite, benazeprilat, by the liver of dogs with ascitic pulmonary heartworm disease. The Journal of veterinary medical science / the Japanese Society of Veterinary Science. 65(6): 701-6. PMID: 12867730
2. Toutain, P L., et al., 2004. Pharmacokinetics and pharmacokinetic/pharmacodynamic relationships for angiotensin-converting enzyme inhibitors. Journal of veterinary pharmacology and therapeutics. 27(6): 515-25. PMID: 15601445
3. Wang, Xue-Ding., et al., 2007. Simultaneous and rapid quantitation of benazepril and benazeprilat in human plasma by high performance liquid chromatography with ultraviolet detection. Journal of pharmaceutical and biomedical analysis. 44(1): 224-30. PMID: 17289327
サンタクルーズバイオテクノロジーは生物医学研究市場向けの製品の開発における世界的リーダです。 下記フリー ダイヤルにお電話ください: 1-800-457-3801。Copyright © 2007-2021 Santa Cruz Biotechnology, Inc.全著作権所有。"Santa Cruz Biotechnology"、 及びSanta Cruz Biotechnology, Inc. ロゴ、 "Santa Cruz Animal Health"、 "San Juan Ranch"、 "Supplement of Champions"、 San Juan Ranch ロゴ、 "Ultracruz"、 "Chemcruz"、 "Immunocruz"、 "Exactacruz"、 と "EZ Touch"はサンタクルーズバイオテクノロジーの登録商標です。 商標はそれぞれの所有者に帰属します。